Skip to content
Open access

R0 resection following neoadjuvant PD-1 inhibition with paclitaxel-cisplatin is associated with improved overall survival in locally advanced and recurrent oral squamous cell carcinoma: multicenter retrospective cohort study

Oct 2026 · Annals medicus · Vol 58 · 0 citations · 31 references
Medicine

TL;DR

In treatment-naive and recurrent LA-OSCC, neoadjuvant chemoimmunotherapy followed by response-directed R0 resection and risk-adapted radiotherapy was associated with improved OS, and retrospective associations warrant confirmation in prospective randomized trials.

Abstract

Abstract Background Locally advanced oral squamous cell carcinoma (LA-OSCC) has poor prognosis with standard therapy; recurrent disease is palliative. We compared neoadjuvant PD-1 inhibition plus paclitaxel-cisplatin followed by R0 resection ± radiotherapy versus non-surgical treatment in treatment-naive and recurrent LA-OSCC. Methods This multicenter retrospective study (2021–2024) included 178 stage III–IVb LA-OSCC patients (43 recurrent, 135 treatment-naive) receiving neoadjuvant chemoimmunotherapy. The primary endpoint was overall survival (OS), analyzed using multivariable time-dependent Cox regression, propensity score matching (PSM), inverse probability of treatment weighting (IPTW), and landmark analyses Results The overall response rate was 66.3%; the pathological complete response rate among 117 surgical patients was 35.0%. Responders had better OS than non-responders (HR 0.19, 95%CI 0.11–0.32, p < 0.001). Surgery was associated with improved OS versus non-surgical management (HR 0.23, 95%CI 0.13–0.39, p < 0.001), and the association remained consistent after multivariable adjustment (HR 0.29, 95%CI 0.16–0.52), PSM (47 pairs; HR 0.34, 95%CI 0.17–0.66), IPTW (HR 0.36, 95% CI 0.18–0.74), and 6-month landmark analysis (HR 0.22, 95%CI 0.13–0.39). Radiotherapy was also associated with improved OS (HR 0.43, 95%CI 0.21–0.87, p = 0.018); postoperative radiotherapy was associated with longer OS than surgery alone (HR 0.43, 95%CI 0.16–0.98, p = 0.047), and surgery was associated with improved OS in recurrent disease (HR 0.47, 95%CI 0.21–0.99, p = 0.049). Conclusion In treatment-naive and recurrent LA-OSCC, neoadjuvant chemoimmunotherapy followed by response-directed R0 resection and risk-adapted radiotherapy was associated with improved OS. These retrospective associations warrant confirmation in prospective randomized trials.

Read PDF

Similar papers

Open access Oct 2026

Definitive radiotherapy versus surgery after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma: a propensity score-matched study of efficacy and safety

Comparing the survival outcomes and recurrence patterns of radical surgery and definitive radiotherapy following NICT in patients with LA-ESCC concluded that Definitive RT may be an organ-preserving option in selected patients, especially those with upper esophageal cancer or a favorable response to NICT.

Q. An, Ya-Ge Jia, Meng-Lu Liu et al. · 0 citations
Open access Oct 2026

Comparison of neoadjuvant treatment strategies in resectable locally advanced esophageal squamous cell carcinoma: A real-world study

In this retrospective real-world cohort, pCR and toxicity profiles differed among the three neoadjuvant strategies, whereas no statistically significant differences in PFS or OS were detected after overlap weighting.

Xiao-Han Wang, Jing-Jing Liu, Jie Cui et al. · 0 citations
Open access Oct 2026

Comparative effectiveness of neoadjuvant treatment strategies and predictors of pathological complete response in locally advanced esophageal squamous cell carcinoma: a real-world retrospective cohort study

Objective To compare pathological complete response (pCR) across different neoadjuvant treatment strategies in patients with locally advanced esophageal squamous cell carcinoma (ESCC) and to identify clinicopathological factors associated with pCR. Methods In this single-center retrospective cohort study, 247 consecuti...

Xiao-Li Yuan, Yu-Ying Liang, T. Han et al. · 0 citations
Open access Oct 2026

Role of postoperative radiotherapy in locally advanced esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy: A retrospective propensity score-matched study

Although neoadjuvant immunochemotherapy (NCIT) has shown promising prospects in the treatment of locally advanced esophageal squamous cell carcinoma (LA-ESCC), the role of adjuvant radiotherapy in these patients remains unclear. This study aimed to investigate the impact of postoperative adjuvant radiotherap...

Li Li, X. Jing, Ming-Juan Sun et al. · 0 citations
Open access Sep 2026

Neoadjuvant Anlotinib Plus Paclitaxel-Cisplatin for Technically Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Prospective Single-Arm Phase II Study.

BACKGROUND Technically resectable locally advanced head and neck squamous cell carcinoma may require highly morbid surgery. We evaluated short-course neoadjuvant anlotinib plus paclitaxel-cisplatin as a signal-generating strategy. METHODS Twenty-one patients received two 21-day cycles in a prospective, single-arm Pha...

Ran Xu, M.-J. Huang, Zhen-Hua Jiang et al. · 0 citations
Sep 2026

Abstract B038: Long-term outcomes following surgical resection in a three-center subset of a randomized phase II trial of dose-escalated radiotherapy for borderline resectable and locally advanced pancreatic cancer

Surgical resection following neoadjuvant therapy is associated with prolonged survival in borderline resectable and locally advanced pancreatic cancer (BRPC/LAPC), yet whether this reflects improved local disease control alone or identifies patients with intrinsically favorable disease biology remains uncertain....

Todd A. Aguilera, P. Parikh, J. Frakes et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.